Biopharmaceutical Development of a Bifonazole Multiple Emulsion for Enhanced Epidermal Delivery

dc.contributor.authorSuñer Carbó, J. (Joaquim)
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorHalbaut, Lyda
dc.contributor.authorClares Naveros, Beatriz
dc.contributor.authorRodríguez Lagunas, María José
dc.contributor.authorBarbolini, Elena
dc.contributor.authorZamarbide Losada, Joanna
dc.contributor.authorBoix Montañés, Antonio de Pádua
dc.date.accessioned2020-05-18T07:40:51Z
dc.date.available2020-05-18T07:40:51Z
dc.date.issued2019-02-02
dc.date.updated2020-05-18T07:40:52Z
dc.description.abstractEfficient topical delivery of imidazolic antifungals faces the challenge of overcoming its limited water solubility and its required long-lasting duration of treatments. In this paper, a hydrophilic multiple emulsion (ME) of Bifonazole (BFZ) is shown to maximize its skin retention, minimize its skin permeation, and maintain an acceptable level of being harmless in vivo. The formulations were pharmaceutically characterized and application properties were assessed based on viscosity measurements. Non-Newtonian pseudoplastic shear thinning with apparent thixotropy was observed, facilitating the formulation retention over the skin. The in vitro release profile with vertical diffusion cells showed a predominant square-root release kinetic suggesting an infinite dose depletion from the formulation. Ex vivo human skin permeation and penetration was additionally evaluated. Respective skin permeation was lower than values obtained with a commercial O/W formulation. The combination of amphoteric and non-ionic surfactants increased the bifonazole epidermal accumulation by a factor of twenty. This fact makes the possibility of increasing its current 24 h administration frequency more likely. Eventual alterations of skin integrity caused by the formulations were examined with epidermal histological analysis and in vivo preclinical measurements of skin elasticity and water retrograde permeation. Histological analysis demonstrated that the multiple emulsions were harmless. Additionally, modifications of in vivo skin integrity descriptors were considered as negligible.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691102
dc.identifier.issn1999-4923
dc.identifier.pmid30717419
dc.identifier.urihttps://hdl.handle.net/2445/160808
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics11020066
dc.relation.ispartofPharmaceutics, 2019, vol. 11, num. 2, p. 66
dc.relation.urihttps://doi.org/10.3390/pharmaceutics11020066
dc.rightscc-by (c) Suñer Carbó, J. (Joaquim) et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Bioquímica i Fisiologia)
dc.subject.classificationEmulsions (Farmàcia)
dc.subject.classificationPell
dc.subject.classificationAgents tensioactius
dc.subject.otherEmulsions (Pharmacy)
dc.subject.otherSkin
dc.subject.otherSurface active agents
dc.titleBiopharmaceutical Development of a Bifonazole Multiple Emulsion for Enhanced Epidermal Delivery
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
691102.pdf
Mida:
3.97 MB
Format:
Adobe Portable Document Format